Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta-analysis

Cancer Medicine

Volumn 8, Issue 2, 2019, Pages 480-491

  Zhang, Xinyu ^a   Zhu, Xiaoqiang ^a   Cao, Yingying ^a   Fang, Jing Yuan ^a   Hong, Jie ^a   Chen, Haoyan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

colorectal cancer; diagnosis; feces; Fusobacterium nucleatum

Indexed keywords

ARTICLE; COLORECTAL ADENOMA; COLORECTAL TUMOR; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DNA EXTRACTION; FECES ANALYSIS; FUSOBACTERIUM NUCLEATUM; HUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; FECES; ISOLATION AND PURIFICATION; META ANALYSIS; MICROBIOLOGY;

BIOLOGICAL MARKER;

BIOMARKERS; COLORECTAL NEOPLASMS; FECES; FUSOBACTERIUM NUCLEATUM; HUMANS;

EID: 85059910040     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1850     Document Type: Article

References (47)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
2. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
3. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008. Am J Gastroenterol. 2009;104:739.
4. Sung J, Ng SC, Chan F, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64(1):121-132.
5. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171-181.
6. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150(3):162-169.
7. Shapiro JA, Bobo JK, Church TR, et al. A comparison of fecal immunochemical and high-sensitivity guaiac tests for colorectal cancer screening. Am J Gastroenterol. 2017;112:1728-1735.
8. Cubiella J, Castro I, Hernandez V, et al. Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening. United Eur Gastroenterol J. 2014;2(6):522-529.
9. Cubiella J, Castro I, Hernandez V, et al. Characteristics of adenomas detected by fecal immunochemical test in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1884-1892.
10. van Turenhout ST, Oort FA, Terhaar sive Droste JS, et al. Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results. Gastrointest Endosc. 2012;76(1):136-143.
11. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299-306.
12. Holt RA, Cochrane K. Tumor potentiating mechanisms of Fusobacterium nucleatum, a multifaceted microbe. Gastroenterology. 2017;152(4):694-696.
13. Fukugaiti MH, Ignacio A, Fernandes MR, Ribeiro U, Nakano V, Avila-Campos MJ. High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients. Brazilian J Microbiol. 2015;46(4):1135-1140.
14. Eklöf V, Löfgren-Burström A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017;141(12):2528-2536.
15. Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 2017;23(8):2061-2070.
16. Wong SH, Kwong T, Chow T-C, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017;66(8):1441-1448.
17. Amitay EL, Werner S, Vital M, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis. 2017;38(8):781-788.
18. Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10(11):766.
19. Xie Y-H, Gao Q-Y, Cai G-X, et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine. 2017;25:32-40.
20. Whiting PF, Rutjes AW, Westwood ME, et al. Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
21. Reitsma JB, Glas AS, Rutjes A, Scholten R, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982-990.
22. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865-2884.
23. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882-893.
24. Higgins J, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327(7414):557-560.
25. Suehiro Y, Sakai K, Nishioka M, et al. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann Clin Biochem. 2016;54(1):86-91.
26. Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol. 2015;50(2):167-179.
27. Guo S, Li L, Xu B et al. A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin Chem. 2018;64(9):1327-1337.
28. Abed J, Emgård J, Zamir G, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20(2):215-225.
29. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206.
30. Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851-866.e24.
31. Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344-355.
32. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T-cells in Colorectal Carcinoma. JAMA Oncol. 2015;1(5):653-661.
33. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207-215.
34. Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548-563.e16.
35. Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53(4):517-524.
36. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973-1980.
37. Yu J, Chen Y, Fu X, et al. Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. Int J Cancer. 2016;139(6):1318-1326.
38. Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381-1390.
39. Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70-78.
40. Costea PI, Zeller G, Sunagawa S, et al. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017;35:1069.
41. O’Keefe S, Li JV, Lahti L, et al. Fat, fiber and cancer risk in African Americans and Rural Africans. Nat Commun. 2015;6:6342.
42. Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Diet-induced extinction in the gut microbiota compounds over generations. Nature. 2016;529(7585):212-215.
43. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585.
44. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathologic epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397-411.
45. Ogino S, Nishihara R, VanderWeele TJ, et al. The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27(4):602-611.
46. Rutjes A, Reitsma JB, Vandenbroucke JP, Glas AS. Bossuyt PMM. Case–control and two-gate designs in diagnostic accuracy studies. Clin Chem. 2005;51(8):1335-1341.
47. Sox HC. The evaluation of diagnostic tests: principles, problems, and new developments. Annu Rev Med. 1996;47(1):463-471.